Advanced Medical Isotope (OTCMKTS:RDGL) & Runway Growth Finance (NASDAQ:RWAY) Head to Head Comparison

Runway Growth Finance (NASDAQ:RWAY) and Advanced Medical Isotope (OTCMKTS:RDGL) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Volatility & Risk

Runway Growth Finance has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.5, meaning that its share price is 150% less volatile than the S&P 500.

Profitability

This table compares Runway Growth Finance and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Runway Growth Finance	38.92%	11.94%	5.80%
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%

Institutional and Insider Ownership

64.6% of Runway Growth Finance shares are owned by institutional investors. 1.0% of Runway Growth Finance shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Runway Growth Finance and Advanced Medical Isotope”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Runway Growth Finance	$144.63 million	2.32	$73.61 million	$1.47	6.31
Advanced Medical Isotope	$30,000.00	1,008.15	-$2.91 million	N/A	N/A

Runway Growth Finance has higher revenue and earnings than Advanced Medical Isotope.

Analyst Ratings

This is a breakdown of current ratings and target prices for Runway Growth Finance and Advanced Medical Isotope, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Runway Growth Finance	0	4	3	0	2.43
Advanced Medical Isotope	0	0	0	0	0.00

Runway Growth Finance presently has a consensus price target of $11.10, suggesting a potential upside of 19.61%. Given Runway Growth Finance’s stronger consensus rating and higher possible upside, equities analysts plainly believe Runway Growth Finance is more favorable than Advanced Medical Isotope.

Summary

Runway Growth Finance beats Advanced Medical Isotope on 10 of the 12 factors compared between the two stocks.

About Runway Growth Finance

Runway Growth Finance Corp. is a business development company specializing investments in senior-secured loans to late stage and growth companies. It prefers to make investments in companies engaged in the technology, life sciences, healthcare and information services, business services and select consumer services and products sectors. It prefers to investments in companies engaged in electronic equipment and instruments, systems software, hardware, storage and peripherals and specialized consumer services, application software, healthcare technology, internet software and services, data processing and outsourced services, internet retail, human resources and employment services, biotechnology, healthcare equipment and education services. It invests in senior secured loans between $10 million and $75 million.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.